Harmony Biosciences Holdings (HRMY) Long-Term Deferred Tax (2022 - 2026)

Harmony Biosciences Holdings' Long-Term Deferred Tax history runs 5 years deep, the most recent figure standing at $153.6 million for Q1 2026.

• In Q1 2026, Long-Term Deferred Tax fell 21.13% year-over-year to $153.6 million; the TTM figure through Mar 2026 stood at $153.6 million (down 21.13% YoY), while the FY2025 annual figure was $149.7 million, down 21.38% from the prior year.
• Long-Term Deferred Tax came in at $153.6 million for Q1 2026 at Harmony Biosciences Holdings, up from $149.7 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $201.2 million in Q2 2025 to a low of $81.7 million in Q3 2022.
• A 5-year average of $143.6 million and a median of $149.7 million in 2025 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax jumped 92.55% in 2024 and decreased 21.38% in 2025, its largest moves.
• Harmony Biosciences Holdings' Long-Term Deferred Tax stood at $85.9 million in 2022, then soared by 67.74% to $144.2 million in 2023, then soared by 32.07% to $190.4 million in 2024, then fell by 21.38% to $149.7 million in 2025, then advanced by 2.58% to $153.6 million in 2026.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $153.6 million, $149.7 million, and $157.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison